HI
ADIL

Harbour Investments’s Adial Pharmaceuticals ADIL Stock Holding History

Harbour Investments’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8 Hold
3
– – ﹤0.01% 4742
2026
Q1 		$5 Sell
3
-1
-25% -$4 ﹤0.01% 4651
2025
Q4 		$22 Buy
+4
New +$32 ﹤0.01% 3822

Other funds holding ADIL

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCM
Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Harbour Investments's ADIL Position: Q2 2026 in Review

Harbour Investments held its Adial Pharmaceuticals (ADIL) position steady in Q2 2026 at 3 shares worth $8. The position accounts for ﹤0.01% of the portfolio, ranked #4742.

Harbour Investments first reported a position in ADIL in Q4 2025 and has held it in 3 quarters since. The position peaked at $22 in Q4 2025. 17 funds tracked by Wall St. Rank hold ADIL as of Q2 2026.

  • Harbour Investments held 3 shares of Adial Pharmaceuticals worth $8 as of Q2 2026.
  • Harbour Investments left its Adial Pharmaceuticals share count unchanged in Q2 2026.
  • Adial Pharmaceuticals made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4742 holding.
  • Harbour Investments first reported a position in Adial Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Harbour Investments's Adial Pharmaceuticals position peaked at $22 in Q4 2025.
  • 17 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.